BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Business Wire

11:00 AM | Saturday | Aug 29, 2026

news photo
Loading...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).

Read full article redirect
11:00 AM | Saturday | Aug 29, 2026

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).

Read full article arrow
News Thumbnail
10:15 AM | Saturday | Aug 29, 2026

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

The Motley Fool

Bristol Myers Squibb's cardiovascular drug Eliquis is set to lose patent protection in 2028. The company is busy bringing out new drugs and developing more to offset the revenue it will lose.

Read full article arrow
News Thumbnail
4:08 AM | Saturday | Aug 29, 2026

232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC

Defense World

Beacon Pointe Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 232,697 shares of the biopharmaceutical company's stock, valued at approximately $13,408,000. A number

Read full article arrow
News Thumbnail
10:03 AM | Friday | Aug 28, 2026

Bank OZK Invests $474,000 in Bristol Myers Squibb Company $BMY

Defense World

Bank OZK bought a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 8,232 shares of the biopharmaceutical company's stock, valued at approximately $474,000. A number of other institutional investors have also made

Read full article arrow
News Thumbnail
4:26 AM | Friday | Aug 28, 2026

Ancora Advisors LLC Takes $1.39 Million Position in Bristol Myers Squibb Company $BMY

Defense World

Ancora Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,068 shares of the biopharmaceutical company's stock, valued at approximately $1,387,000. A number

Read full article arrow
News Thumbnail
11:36 AM | Thursday | Aug 27, 2026

Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

Zacks Investment Research

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.

Read full article arrow
News Thumbnail
3:20 PM | Tuesday | Aug 25, 2026

PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?

Zacks Investment Research

PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.

Read full article arrow
News Thumbnail
2:00 PM | Tuesday | Aug 25, 2026

3 Dividend Stocks to Hold for the Next 10 Years

Fool - Investing News

These healthcare leaders are unlikely to suspend their dividend programs.

Read full article arrow
News Thumbnail
12:58 PM | Tuesday | Aug 25, 2026

Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares

Reuters

Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its ​personalized blood cancer therapy, a company spokesperson told ‌Reuters on Tuesday.

Read full article arrow
News Thumbnail
8:20 AM | Monday | Aug 24, 2026

JP Morgan Warns of Fall Sell-Off Potential: 5 Defensive Dividend Stocks to Buy

247 Wallst

J.P. Morgan's technical team sees deteriorating market internals and a pattern eerily similar to the months before the 1999 tech crash. Five dividend-paying stocks across defensive sectors may offer shelter if the autumn sell-off materializes.

Read full article arrow
News Thumbnail